Ahmed K, Yenice S, Davis A, Goueli SA. Association of casein kinase 2 with nuclear chromatin in relation to androgenic regulation of rat prostate. Proc Natl Acad Sci USA. 1993;90(10):4426–30.

Article  PubMed  PubMed Central  Google Scholar 

Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 2002;12(5):226–30.

Article  PubMed  Google Scholar 

Ahmed K, Kren BT, Abedin MJ, Vogel RI, Shaughnessy DP, Nacusi L, et al. CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors. Oncotarget. 2016;7(38):61789–805.

Article  PubMed  PubMed Central  Google Scholar 

Ahmed K, Unger GM, Kren BT, Trembley JH. Targeting CK2 for cancer therapy using a nanomedicine approach. In: Ahmed K, Issinger, O-G., Szyszka R, editors. Protein Kinase CK2 in cellular function in normal and disease states. Advances in biochemistry in health and disease. 12. Switzerland: Springer International Publishing Switzerland; 2015. p. 299–315.

Al-Kafaji G, Al-Naieb ZT, Bakhiet M. Increased oncogenic microRNA-18a expression in the peripheral blood of patients with prostate cancer: a potential novel non-invasive biomarker. Oncol Lett. 2016;11(2):1201–6.

Article  PubMed  Google Scholar 

Baltan S, Sandau US, Brunet S, Bastian C, Tripathi A, Nguyen H, et al. Identification of miRNAs that mediate protective functions of anti-cancer drugs during white matter ischemic injury. ASN Neuro. 2021;13:17590914211042220.

Article  PubMed  PubMed Central  Google Scholar 

Bartel DP. Metazoan MicroRNAs. Cell. 2018;173(1):20–51.

Article  PubMed  Google Scholar 

Bhagirath D, Yang TL, Bucay N, Sekhon K, Majid S, Shahryari V, et al. microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer. Cancer Res. 2018;78(7):1833–44.

Article  PubMed  Google Scholar 

Borgo C, Ruzzene M. Role of protein kinase CK2 in antitumor drug resistance. J Exp Clin Cancer Res. 2019;38(1):287.

Article  PubMed  Google Scholar 

Buchou T, Vernet M, Blond O, Jensen HH, Pointu H, Olsen BB, et al. Disruption of the regulatory b subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol. 2003;23(3):908–15.

Article  PubMed  Google Scholar 

Costa R, Arrigoni G, Cozza G, Lolli G, Battistutta R, Izpisua Belmonte JC, et al. The lysine-specific demethylase 1 is a novel substrate of protein kinase CK2. Biochim Biophys Acta. 2014;1844(4):722–9.

Article  PubMed  Google Scholar 

Deplus R, Blanchon L, Rajavelu A, Boukaba A, Defrance M, Luciani J, et al. Regulation of DNA methylation patterns by CK2-mediated phosphorylation of Dnmt3a. Cell Rep. 2014;8(3):743–53.

Article  PubMed  Google Scholar 

Dragomir MP, Knutsen E, Calin GA. Classical and noncanonical functions of miRNAs in cancers. Trends Genet. 2022;38(4):379–94.

Article  PubMed  Google Scholar 

Faust M, Montenarh M. Subcellular localization of protein kinase CK2. A key to its function? Cell Tissue Res. 2000;301(3):329–40.

Article  PubMed  Google Scholar 

Faust RA, Niehans G, Gapany M, Hoistad D, Knapp D, Cherwitz D, et al. Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int J Biochem Cell Biol. 1999;31(9):941–9.

Article  PubMed  Google Scholar 

Feng S, Qian X, Li H, Zhang X. Combinations of elevated tissue miRNA-17-92 cluster expression and serum prostate-specific antigen as potential diagnostic biomarkers for prostate cancer. Oncol Lett. 2017;14(6):6943–9.

PubMed  Google Scholar 

Guerra B, Issinger OG. Protein kinase CK2 in human diseases. Curr Med Chem. 2008;15(19):1870–86.

Article  PubMed  Google Scholar 

Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–24.

Article  PubMed  Google Scholar 

Hossain MM, Sultana A, Barua D, Islam MN, Gupta A, Gupta S. Differential expression, function and prognostic value of miR-17-92 cluster in ER-positive and triple-negative breast cancer. Cancer Treat Res Commun. 2020;25: 100224.

Article  PubMed  Google Scholar 

Hsu TI, Hsu CH, Lee KH, Lin JT, Chen CS, Chang KC, et al. MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo. Oncogenesis. 2014;3: e99.

Article  PubMed  Google Scholar 

Huang Q, Shen YJ, Hsueh CY, Guo Y, Zhang YF, Li JY, Zhou L. miR-17-5p drives G2/M-phase accumulation by directly targeting CCNG2 and is related to recurrence of head and neck squamous cell carcinoma. BMC Cancer. 2021;21(1):1074.

Article  PubMed  Google Scholar 

Jurkovicova D, Smolkova B, Magyerkova M, Sestakova Z, Kajabova VH, Kulcsar L, et al. Down-regulation of traditional oncomiRs in plasma of breast cancer patients. Oncotarget. 2017;8(44):77369–84.

Article  PubMed  Google Scholar 

Kelly BD, Miller N, Healy NA, Walsh K, Kerin MJ. A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int. 2013;111(1):17–21.

Article  PubMed  Google Scholar 

Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, et al. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Sci Rep. 2018;8(1):7189.

Article  PubMed  Google Scholar 

Li D, Chen L, Hu Z, Li H, Li J, Wei C, et al. Alterations of microRNAs are associated with impaired growth of MCF-7 breast cancer cells induced by inhibition of casein kinase 2. Int J Clin Exp Pathol. 2014;7(7):4008–15.

PubMed  Google Scholar 

Li R, Qu H, Wang S, Chater JM, Wang X, Cui Y, et al. CancerMIRNome: an interactive analysis and visualization database for miRNome profiles of human cancer. Nucleic Acids Res. 2022;50(1):1139–46.

Article  Google Scholar 

Liu H, Hou T, Ju W, Xing Y, Zhang X, Yang J. MicroRNA-122 downregulates Rho-associated protein kinase 2 expression and inhibits the proliferation of prostate carcinoma cells. Mol Med Rep. 2019;19(5):3882–8.

PubMed  Google Scholar 

Liu X, Haniff HS, Childs-Disney JL, Shuster A, Aikawa H, Adibekian A, Disney MD. Targeted degradation of the oncogenic MicroRNA 17–92 cluster by structure-targeting ligands. J Am Chem Soc. 2020;142(15):6970–82.

Article  PubMed  Google Scholar 

Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O’Brien C, Seldin DC. The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol. 2008;28(1):131–9.

Article  PubMed  Google Scholar 

Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–7.

Article  PubMed  Google Scholar 

Marschke RF, Borad MJ, McFarland RW, Alvarez RH, Lim JK, Padgett CS, et al. Findings from the phase I clinical trials of CX-4945, an orally available inhibitor of CK2. J Clin Oncol. 2011;29(15_supply):3087.

Article  Google Scholar 

Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003;17(3):349–68.

Article  PubMed  Google Scholar 

Mehlich D, Garbicz F, Włodarski PK. The emerging roles of the polycistronic miR-106b∼25 cluster in cancer–a comprehensive review. Biomed Pharmacother. 2018;107:1183–95.

Article  PubMed  Google Scholar 

Mishra S, Yadav T, Rani V. Exploring miRNA based approaches in cancer diagnostics and therapeutics. Crit Rev Oncol Hematol. 2016;98:12–23.

Article  PubMed  Google Scholar 

Moi L, Braaten T, Al-Shibli K, Lund E, Busund LR. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian women and cancer (NOWAC) study. J Transl Med. 2019;17(1):334.

Article  PubMed  PubMed Central  Google Scholar 

Morales S, Monzo M, Navarro A. Epigenetic regulation mechanisms of microRNA expression. Biomol Concepts. 2017;8(5–6):203–12.

Article  PubMed  Google Scholar 

Nuñez de Villavicencio-Diaz T, Rabalski AJ, Litchfield DW. Protein kinase CK2: intricate relationships within regulatory cellular networks. Pharmaceuticals. 2017;10(1):27.

Article  PubMed  PubMed Central